Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14560485 | 0.86 | CYP19A1 (0.56) | KMT2ATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL14560486 | 0.83 | CYP19A1 (0.57) | KMT2ATSHRCYP19A1MEN1POLB | |
| SCHEMBL9800237 | 0.73 | KMT2A (0.69) | KMT2ATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL9472654 | 0.73 | KMT2A (0.38) | KMT2ATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL3459302 | 0.73 | ADRA1D (0.56) | TSHRADRA1DADRA1AADRA1B | |
| SCHEMBL14560410 | 0.71 | CYP19A1 (0.74) | KMT2ATSHRCYP19A1MEN1POLB | |
| SCHEMBL21389402 | 0.70 | FABP3 (0.41) | KMT2ATSHR | |
| SCHEMBL21389401 | 0.70 | DRD2 (0.43) | DRD2DDB1CRBN | |
| SCHEMBL8364956 | 0.69 | CYP19A1 (0.76) | KMT2ATSHRCYP19A1 | |
| SCHEMBL11844494 | 0.69 | KMO (0.43) | TSHRSRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487444-B9 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-07-21 | — | — | EP | claimed |
| EP-1487444-B1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2009-12-30 | — | — | EP | claimed |
| US-20060052419-A1 | Use of pyridly amides as inhibitors of angiogenesis | ASTELLAS DEUTSCHLAND GMBH (DE) | 2006-03-09 | — | — | US | claimed |
| EP-1348434-A1 | Use of pyridyl amides as inhibitors of angiogenesis | Fujisawa Deutschland GmbH (DE) | 2003-10-01 | — | — | EP | claimed |
| EP-1487444-B9 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-07-21 | — | — | EP | disclosed |
| EP-1487444-B1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20060052419-A1 | Use of pyridly amides as inhibitors of angiogenesis | ASTELLAS DEUTSCHLAND GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
| EP-1348434-A1 | Use of pyridyl amides as inhibitors of angiogenesis | Fujisawa Deutschland GmbH (DE) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052419-A1 | Use of pyridly amides as inhibitors of angiogenesis | FLT1, VEGFA, FLT4 | KMT2A 3804/4885TSHR 2378/4885CHRM2 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.